

CORRECTION

Open Access



# Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia

Jessica M. Salmon<sup>1,5</sup>, Michael Bots<sup>2</sup>, Eva Vidacs<sup>1</sup>, Kym L. Stanley<sup>1</sup>, Peter Atadja<sup>3</sup>, Johannes Zuber<sup>4</sup> and Ricky W. Johnstone<sup>1,5\*</sup>

**Correction to: Clinical Epigenetics (2015) 7:2,**

<https://doi.org/10.1186/s13148-014-0034-4>

Following publication of the original article [1], the authors identified an error in Fig. 2e. The correct Fig. 2 is given below.

---

The original article can be found online at <https://doi.org/10.1186/s13148-014-0034-4>.

\*Correspondence: [ricky.johnstone@petermac.org](mailto:ricky.johnstone@petermac.org)


<sup>1</sup> Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St.

Andrews Place, East Melbourne, VIC 3002, Australia

Full list of author information is available at the end of the article



© The Author(s) 2020. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



(See figure on previous page.)

**Fig. 2** The combined effects of panobinostat and arsenic trioxide (ATO) include the differentiation of *A/E9a;Nras*<sup>G12D</sup>-leukemic blasts by panobinostat and induction of apoptosis by ATO. **(A)** Flow cytometry analysis of the cell surface expression of c-Kit; Sca1; Mac1 and Gr1 of GFP-positive tumor cells in the bone marrow of *A/E9a;Nras*<sup>G12D</sup> tumor-bearing mice treated for 5 days with either panobinostat (pan; 25 mg/kg) or panobinostat combined with ATO (2.5 mg/kg). (n = 3; data are expressed as mean plus SEM; \**P* < 0.05, \*\**P* < 0.001) **(B)** Representative dot plots of AnnexinV-PI staining of tumor cells isolated from the bone marrow of *A/E9a;Nras*<sup>G12D</sup> tumor-bearing mice treated for 4 hours with either panobinostat (25 mg/kg) or ATO (2.5 mg/kg) or a combination. Numbers given are the percentage of total cell population. **(C)** Normalized expression of AnnexinV on tumor cells treated with vehicle, panobinostat, ATO or a combination (n = 3; data are expressed as mean plus SEM). **(D)** Quantification of terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) positivity as a proportion of total cell area (n = 3; \**P* < 0.001) **(E)** Representative images of hematoxylin-eosin staining (H&E; upper panels) and analysis of apoptotic cells by TUNEL staining and counterstained with hematoxylin (lower panels). Staining was performed on de-calcified femurs isolated from *A/E9a;Nras*<sup>G12D</sup> tumor-bearing mice treated for 4 hours as indicated. Imaging was performed using 60x objective (scale bars = 50 μm).

#### Author details

<sup>1</sup> Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC 3002, Australia. <sup>2</sup> Laboratory of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. <sup>3</sup> China Novartis Institutes for Biomedical Research, No. 2 BoYun Road, Pudong, Shanghai 201203, China. <sup>4</sup> Research Institute of Molecular Pathology (IMP), Dr. Bohr-Gasse 7, A-1030 Vienna, Austria. <sup>5</sup> The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.

#### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published online: 18 November 2020